TAVR

TAVR with Sapien XT: similar to surgical replacement in intermediate risk patients

Original Title: Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. PARTNER 2A. Reference: Martin B. Leon et al. NEJM April 2, 2016 Courtesy of Dr. Juan A. Terré Studies have shown mortality rates after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in high risk patients are similar (PARTNER 2 Cohort B). This is<a href="https://solaci.org/en/2016/04/15/tavr-with-sapien-xt-similar-to-surgical-replacement-in-intermediate-risk-patients/" title="Read more" >...</a>

New York TAVR Registry: Trends in use and mortality at one year

Original Title: Utilization and 1-Year Mortality for Transcatheter Aortic Valve Replacement and Surgical Aortic Valve Replacement in New York Patients With Aortic Stenosis2011 to 2012. Reference:Hannan EL et al. J Am CollCardiolIntv. 2016;9(6):578-585. Courtesy of Dr. Agustín Vecchia Its been only 14 years sinceCribierperformed the first transcatheter valve replacement. Today, during 2016, 100,000 patients are expected to<a href="https://solaci.org/en/2016/04/08/new-york-tavr-registry-trends-in-use-and-mortality-at-one-year/" title="Read more" >...</a>

TAVR-LM Registry: Transcatheter Aortic Valve Replacement and Left Main Stenting

Original Title: Outcomes in Patients with Transcatheter Aortic Valve Replacement and Left Main Stenting. The TAVR-LM Registry. Reference: TarunChakravarty et al. Journal of the American College of Cardiology, Vol 67, N° 8, 2016. Courtesy of Dr. Santiago F. Coroleu.  High surgical risk patients with severe aortic stenosis and significant left main aortic arterydiseaseare often treated combining<a href="https://solaci.org/en/2016/03/22/tavr-lm-registry-transcatheter-aortic-valve-replacement-and-left-main-stenting/" title="Read more" >...</a>

TAVR é um procedimento tão seguro e eficaz quanto a substituição cirúrgica num seguimento de dois anos em pacientes de menor risco.

Fundamentos e &nbsp;Objetivos: A substitui&ccedil;&atilde;o da v&aacute;lvula a&oacute;rtica via transcateter (TAVR) &eacute; uma op&ccedil;&atilde;o em determinados pacientes cir&uacute;rgicos de alto risco com estenose da v&aacute;lvula a&oacute;rtica grave. Desconhecemos se a TAVR pode ser introduzida com seguran&ccedil;a para os pacientes de baixo risco. O estudo NOTION (Nordic Aortic Valve Intervention Trial) &eacute; um ensaio cl&iacute;nico randomizado<a href="https://solaci.org/en/2015/06/24/tavr-e-um-procedimento-tao-seguro-e-eficaz-quanto-a-substituicao-cirurgica-num-seguimento-de-dois-anos-em-pacientes-de-menor-risco-2/" title="Read more" >...</a>

NOTION: TAVR in low-risk patients

The aim of this study was to compare the results of transcatheter aortic valve replacement (TAVR) versus surgery in unselected patients with severe degenerative aortic stenosis. Patients were randomized 1:1 to TAVR (n = 145) or surgical replacement (n = 135). Those of TAVR group received Medtronic CoreValve self-expanding valve. The femoral access was used<a href="https://solaci.org/en/2015/06/24/notion-tavr-in-low-risk-patients/" title="Read more" >...</a>

Top